Medigene participates at four national and international conferences in January 2017

Martinsried/Munich, 16 December 2016. Medigene AG (FSE: MDG1, Prime Standard) announces its participation at four upcoming scientific and investor conferences:


  • Ringberg Conference 2017

Date: 03 January 2017
Location: Schloss Ringberg, Tegernsee, Germany
            Dr. Markus Dangl, Senior Vice President Research & Pre-Clinical Development, will give a presentation on the topic: "TCRs and neoantigens: The perfect solution for personalized cancer immunotherapy?"

  • Oddo Forum

Date: 05 - 06 January 2017
Location: Lyon, France

  • J.P. Morgan Healthcare Conference

Date: 09 - 12 January 2017
            Location: San Francisco, USA

  • Phacilitate, Cell & Gene World 2017

Date: 17 - 20 January 2017
            Location: Miami, USA
            Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 18 January 2017 a case study in the session: "Optimizing preclinical data packages for efficient cell & gene therapy clinical translation"

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.